Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Fed Circ: Generic doesn’t infringe Metacel MS drug
Americas
Case looked at whether generic treatment infringes ‘fridge temperature limitation method’ | Ruling underscores importance of clear labelling in drug patent infringement suits.   24 April 2025
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
Europe
Following the Unified Patent Court’s recent Meril v Edwards decision, Agathe Michel-de Cazotte & Ben Chapman of Carpmaels & Ransford examine the court’s treatment of obviousness to date.   24 April 2025
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
Americas
As the US legal sector comes under political pressure for its inclusion efforts, LSIPR's sister magazine reveals its Top 100 for 2025, highlighting the individuals fighting to keep progress at the heart of IP.   24 April 2025
Americas
Generative AI is transforming the biotech industry, so it’s crucial to have an IP strategy—in particular, for trade secret and/or patent protection. Dean Pelletier of Pelletier Law explains.   24 April 2025
Europe
Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed.   22 April 2025
Europe
For those willing to undertake the complexity, in vivo cell therapy could redefine the economics and logistics of cell-based treatment, says Adam Gregory of Mewburn Ellis.   22 April 2025
Careers
The firm hired Brent Babcock as a partner in New York, bringing experience in cases involving biotechnology and medical devices.   22 April 2025
Americas
With a career spanning an iconic consumer brand and big pharma, INTA's current president is focused on amplifying the voice of in-house counsel, finds Muireann Bolger.   22 April 2025
Careers
Firm’s chair says Fenwick has been active in market for a long time and “waiting to find the right opportunity to deepen our bench and presence”.   17 April 2025
Americas
The bipartisan legislative push could create big hurdles for drug development, with concerns mounting over limited patent protections and increased litigation risks, hears Marisa Woutersen.   17 April 2025